I

n a blow to Alexion Pharmaceuticals (ALXN), a Canadian government agency ordered the drug maker to lower the price of a rare disease medicine and reimburse the government for “excessive” pricing.

The ruling by the Patented Medicine Prices Review Board follows a long-running struggle that began after the drug maker three years ago refused to lower its price for Soliris, which, depending upon the disease, costs either US$383,000 or $585,000 per patient. The government agency also asked Alexion to repay sales generated by the drug from 2012 through the first half of 2014.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy